science
ARPA-H to Fund Up to $160 Million for Experimental Gene-Editing Treatments for Rare Diseases
The U.S. health research agency will fund seven teams to develop personalized gene editing therapies for rare diseases. The effort sets a three-year deadline for starting clinical trials.
Jul 9, 11:00 AM·1m read1 source
axios.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
ARPA-H announced on July 9, 2026, that it will spend up to $160 million to develop experimental custom gene editing treatments for rare diseases. Stat reported the details of the new program, called THRIVE. The initiative will support seven teams, each focused on groups of conditions that affect different organ systems.
Teams must begin clinical trials by the third year of the program, though some could start earlier. The effort seeks to build on prior successes with individualized gene editing drugs. ARPA-H is the U.S.
Moonshot agency for health research, according to Stat.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
